Phase 1 open-label trial shows SARS-CoV-2 DNA vaccine induces durable immune response
The efficacy and safety of a DNA-based vaccine are investigated, finding that the unique vaccine imparts a robust and long-lasting immunogenic response.
Adao Shutterstock Michael Greenwood Durable Immune Responses Capable Being Boosted Image Credit Coronavirus Disease Covid 19
Source: news-medical.net